Parkinsonian Syndrome Clinical Trial
Official title:
Dynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian Syndrome
This study involves study participants who have been clinically diagnosed with parkinsonian syndrome or who are at-risk for parkinsonian syndrome, have a family history of parkinsonian syndrome or exposure to environmental toxins potentially associated with parkinsonian syndrome. Participants will have brain imaging to assess dopamine transporter density. The imaging data coupled with family history and environmental exposure data may provide important information about potential risk factors for parkinsonian syndrome.
Status | Completed |
Enrollment | 232 |
Est. completion date | January 2013 |
Est. primary completion date | January 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 22 Years and older |
Eligibility |
Inclusion Criteria: - 22 years or older - A clinical diagnosis of Parkinson's disease (PD), positive family history of PD and/or potential exposure to environmental toxins - Normal screening laboratory studies Exclusion Criteria: - Pregnancy - Psychiatric disease other than history of depression - Significant medical disease including abnormalities on screening |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
United States | Institute for Neurodegenerative Disorders | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Institute for Neurodegenerative Disorders | Albany Medical College, Indiana University |
United States,
Koller WC, Langston JW, Hubble JP, Irwin I, Zack M, Golbe L, Forno L, Ellenberg J, Kurland L, Ruttenber AJ, et al. Does a long preclinical period occur in Parkinson's disease? Neurology. 1991 May;41(5 Suppl 2):8-13. Review. — View Citation
Marek, K., J. Seibyl, et al. (1996). "Dopamine transporter and receptor imaging in Parkinsonism. (Presented at the 4th International Congress of Movement Disorders, Vienna, Austria; June, 1996.)." Mov Dis 6.
Marek, K., J. Seibyl, et al. (1999). "[123I] ß-CIT/SPECT: Assessment of determinants of variability in progression of Parkinson's disease." Neurology 52: A91-92.
Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 1996 Apr;119 ( Pt 2):585-91. — View Citation
Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, Baldwin RM, Fussell B, Smith EO, Charney DS, van Dyck C, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995 Oct;38(4):589-98. Erratum in: Ann Neurol. 1996 Mar;39(3):417. van Dyck, C [added]. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CIT uptake is the Specific: Nondisplaceable striatal uptake ratio | 2 yrs | Yes | |
Secondary | CIT uptake measures from at-risk individuals will be compared with healthy subjects. | 2 yrs | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00132626 -
Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome
|
Phase 2 | |
Completed |
NCT00368199 -
Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
|
N/A | |
Completed |
NCT00096876 -
A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients
|
||
Completed |
NCT00117195 -
A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease
|
N/A | |
Completed |
NCT04193527 -
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
|
Phase 3 | |
Completed |
NCT04974034 -
Movement Disorders Analysis Using a Deep Learning Approach
|
||
Completed |
NCT00354003 -
The Study of the Impact of Disclosing Imaging Study Information to Trial Participants
|
||
Completed |
NCT04925622 -
Complex Eye Movements in Parkinson's Disease and Related Movement Disorders
|
||
Completed |
NCT00315250 -
Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease
|
Phase 2 | |
Completed |
NCT00273351 -
Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families
|
Phase 2 | |
Completed |
NCT00129181 -
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease
|
N/A | |
Completed |
NCT00096720 -
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
|
Phase 2 | |
Completed |
NCT00129675 -
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
|
Phase 2 | |
Recruiting |
NCT05110547 -
Multicenter Study of Blood Biomarkers of Mitochondrial and Peroxisomal Metabolism to Differentiate Idiopathic Parkinson's Disease From Related Conditions
|